Editor JaenickeR
On PND 24 and 31, Cyp17a1 mRNA levels of 1 and 2 IU/kg rhGH rats were significantly higher than those of controls
With that caveat, here is what the published Phase 3 data say at peak dose, in adults with obesity and without diabetes: The roughly 6-percentage-point gap between retatrutide and tirzepatide at peak dose, sustained across more than 2,000 participants, is the data point payers and prescribers will spend the next year arguing about
Weight loss during GLP-1 treatment may be associated with changes in how some people experience sweating, though this varies between individuals and scientific evidence for direct effects on thermoregulation is limited
Precision Genetics and Personalized GLP-1 Response Not all men respond identically to GLP-1 medications due to genetic variation in peptide signaling pathways
Timing matters too: consuming cheese with meals rather than as a standalone snack may reduce nausea risk because the medication is already managing a larger food volume